GSA Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

GSA Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$477K	Buy	+168,551	New	+$571K	0.03%	951
2024 Q1	–	Sell	-48,842	Closed	-$320K	–	1841
2023 Q4	$320K	Buy	+48,842	New	+$316K	0.03%	1083
2023 Q1	–	Sell	-54,976	Closed	-$787K	–	1771
2022 Q4	$787K	Buy	+54,976	New	+$866K	0.1%	335
2022 Q2	–	Sell	-10,114	Closed	-$357K	–	1660
2022 Q1	$357K	Buy	+10,114	New	+$339K	0.05%	768
2021 Q3	–	Sell	-8,095	Closed	-$338K	–	1653
2021 Q2	$338K	Buy	+8,095	New	+$314K	0.04%	867

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GSA Capital Partners's MRVI Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Maravai LifeSciences (MRVI) in Q1 2026: 168,551 shares worth $477K. The stake represents 0.03% of the portfolio and ranks #951 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in MRVI as recently as Q4 2023.

GSA Capital Partners first reported a position in MRVI in Q2 2021 and has held it in 5 quarters since. The position peaked at $787K in Q4 2022. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

GSA Capital Partners held 168,551 shares of Maravai LifeSciences worth $477K as of Q1 2026.
Maravai LifeSciences was a new GSA Capital Partners position in Q1 2026.
Maravai LifeSciences made up 0.03% of GSA Capital Partners's portfolio in Q1 2026, its #951 holding.
GSA Capital Partners first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 5 quarters since.
GSA Capital Partners's Maravai LifeSciences position peaked at $787K in Q4 2022.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.